Cystic Fibrosis
📧 Sign up to get email alerts when something new happens for Cystic Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-07Clinical Trial Update: Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis [Phase 4]
Phase 4 trial update for aztreonam for inhalation solution (AZLI) in treating exacerbations of cystic fibrosis; study completed.
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis [Phase 3]
Phase 3 trial update for early Pseudomonas aeruginosa infection in cystic fibrosis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) [Phase 3]
Phase 3 trial evaluating TEZ/IVA (Lumacaftor/Ivacaftor) in experienced CF subjects has completed with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation [Phase 2]
Phase 2 study evaluating VX-661 (elexacaftor) in combination with ivacaftor for chest imaging endpoints in cystic fibrosis patients homozygo…
-
CLINICAL_TRIALS trial_result · 2019-07-26Clinical Trial Update: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection [Phase 3]
Phase 3 extension study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-07-25Clinical Trial Update: EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients [Phase 2]
Phase 2 trial EMPIRE CF evaluated CTX-4430 in adults with cystic fibrosis; study completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations [Phase 4]
Phase 4 clinical trial evaluating ivacaftor in cystic fibrosis patients using ataluren for nonsense mutations has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2019-07-16Clinical Trial Update: Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating multidose safety and tolerability of dose-escalated liposomal amikacin for inhalation (ARIKACE) in cy…
-
CLINICAL_TRIALS trial_result · 2019-07-15Clinical Trial Update: Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF [Phase 1, Phase 2]
A clinical trial update on evaluating and treating pulmonary vascular disease in moderate to severe cystic fibrosis, with Phase 1 and Phase …
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease [Phase 3]
Phase 3 trial update on dynamic contrast enhanced MRI perfusion imaging in congenital heart disease and lung disease has completed.
-
FDA approval · 2019-06-26FDA Approved: TOBRAMYCIN — Original Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved Teva's Tobramycin generic under an Original Application (ANDA). The approval makes this generic Tobramycin available as a t…
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections [Phase 3]
A Phase 3 study evaluating Arikayce in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections has completed with results po…
-
FDA approval · 2019-06-21FDA Approved: SYMDEKO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved Vertex's supplemental application for Symdeko (tezacaftor/ivacaftor), resulting in an updated/expanded label.
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Ready to Use Therapeutic Food (RUTF) to promote growth in cystic fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-17Clinical Trial Update: A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation [Phase 4]
Phase 4 trial evaluating the effect of lumacaftor/ivacaftor on exercise tolerance in cystic fibrosis patients homozygous for F508del-CFTR; c…
-
CLINICAL_TRIALS trial_result · 2019-06-04Clinical Trial Update: Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa [Phase 1, Phase 2]
Clinical trial update for safety and tolerability of Arikayce in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection (Pha…
-
CLINICAL_TRIALS trial_result · 2019-06-04Clinical Trial Update: Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis [Phase 4]
Phase 4 study report on the pharmacokinetics of tedizolid phosphate in cystic fibrosis patients.
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF) [Phase 2]
A Phase 2 clinical trial evaluating docosahexanoic acid in patients with cystic fibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-14Clinical Trial Update: Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase [Phase 2]
Phase 2 trial update on dose escalation of liposomal amikacin for inhalation (ARIKAYCE) in cystic fibrosis completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-05-09Clinical Trial Update: Effectiveness of Pulmozyme in Infants With Cystic Fibrosis [Phase 2]
Phase 2 trial update on Pulmozyme (dornase alfa) effectiveness in infants with cystic fibrosis; results completed and posted.
-
FDA approval · 2019-04-29FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for KALYDECO (ivacaftor) from Vertex Pharmaceuticals Incorporated. The action involves changes t…
-
FDA approval · 2019-04-29FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for KALYDECO (ivacaftor) from Vertex Pharmaceuticals, indicating an expansion or modification of…
-
EMA withdrawal · 2019-03-29EMA Withdrawn: Vantobra (tobramycin) — Pari Pharma GmbH
EMA has withdrawn Vantobra (tobramycin) from the market.
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis [Phase 1, Phase 2]
Phase 1/2 clinical trial update for PTI-428 evaluating safety, tolerability, and pharmacokinetics in cystic fibrosis subjects has completed.
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study) [Phase 2]
Phase 2 clinical trial update of an IV gallium therapy in cystic fibrosis has completed with results posted.